Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma

Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma

Immune checkpoint inhibitor (ICI) shows low response rate in hepatocellular carcinoma (HCC) but the mechanisms underlying ICI resistance remains unclear. Interferon-γ (IFN-γ) has been widely determined as a prototypical antitumor cytokine. However, growing studies suggest that IFN-γ also mediates im...

Full description

Bibliographic Details
Main Authors: Lulu Xie, Mingyu Liu, Mingyue Cai, Wensou Huang, Yongjian Guo, Licong Liang, Weiguo Cai, Jianxin Liu, Wei Liang, Yitong Tan, Miaoling Lai, Liteng Lin, Kangshun Zhu
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Hepatocellular carcinoma
Immunotherapy
IFN-γ
TGF-β1
NSDHL
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223000422

Similar Items

Similar Items